

Valentina Andreasi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4211977/valentina-andreasi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42
papers

380
citations

12
h-index

17
g-index

45
ext. papers

619
ext. citations

3.7
avg, IF

3.72
L-index

#	Paper	IF	Citations
42	How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.. <i>Current Oncology Reports</i> , 2022 , 24, 227	6.3	0
41	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. <i>JAMA Network Open</i> , 2022 , 5, e220290 ^{10.4}	10.4	0
40	Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021 , 111, 273-287	5.6	13
39	Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2021 , 111, 728-738	5.6	3
38	Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. <i>Endoscopic Ultrasound</i> , 2021 , 10, 372-380	3.6	2
37	EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). <i>Cancers</i> , 2021 , 13,	6.6	1
36	Evaluation of factors predicting loss of benefit provided by laparoscopic distal pancreatectomy compared to open approach. <i>Updates in Surgery</i> , 2021 , 1	2.9	0
35	Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors 2021 , 631-640		
34	Update on gastroenteropancreatic neuroendocrine tumors. <i>Digestive and Liver Disease</i> , 2021 , 53, 171-183	3.3	7
33	Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. <i>Diagnostics</i> , 2021 , 11,	3.8	4
32	New Surgical Strategies 2021 , 113-128		
31	CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors. <i>Radiologia Medica</i> , 2021 , 126, 745-760	6.5	27
30	Evaluation of cost-effectiveness among open, laparoscopic and robotic distal pancreatectomy: A systematic review and meta-analysis. <i>American Journal of Surgery</i> , 2021 , 222, 513-520	2.7	1
29	The role of acinar content at pancreatic resection margin in the development of postoperative pancreatic fistula and acute pancreatitis after pancreaticoduodenectomy. <i>Surgery</i> , 2021 , 170, 1215-1222 ^{3.6}	3.6	3
28	Non Functional Pancreatic Neuroendocrine Tumors 2021 , 125-135		
27	A Preoperative Clinical Risk Score Including C-Reactive Protein Predicts Histological Tumor Characteristics and Patient Survival after Surgery for Sporadic Non-Functional Pancreatic Neuroendocrine Neoplasms: An International Multicenter Cohort Study. <i>Cancers</i> , 2020 , 12,	6.6	6
26	A systematic review and meta-analysis on the role of omental or falciform ligament wrapping during pancreaticoduodenectomy. <i>Hpb</i> , 2020 , 22, 1227-1239	3.8	11

25	Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. <i>Current Treatment Options in Oncology</i> , 2020 , 21, 48	5.4	3
24	Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. <i>American Journal of Surgery</i> , 2020 , 220, 284-289	2.7	14
23	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1348-1355	3.1	26
22	Implications of increased serum amylase after pancreaticoduodenectomy: toward a better definition of clinically relevant postoperative acute pancreatitis. <i>Hpb</i> , 2020 , 22, 1645-1653	3.8	12
21	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020 , 35, 141-148	2.5	6
20	Preoperative predictive factors of laparoscopic distal pancreatectomy difficulty. <i>Hpb</i> , 2020 , 22, 1766-1774	3.4	7
19	Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors. <i>Surgery</i> , 2020 , 168, 816-824	3.6	1
18	Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. <i>Nuclear Medicine Communications</i> , 2020 , 41, 896-905	1.6	11
17	Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3928-3936	3.1	10
16	68Ga-DOTA-peptides PET/MRI in pancreatico-duodenal neuroendocrine tumours: a flash pictorial essay on assets and lacks. <i>Clinical and Translational Imaging</i> , 2019 , 7, 363-371	2	4
15	Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). <i>Clinical and Translational Imaging</i> , 2019 , 7, 181-188	2	12
14	Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. <i>Surgery</i> , 2019 , 166, 157-163	3.6	19
13	Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens. <i>Neuroendocrinology</i> , 2019 , 109, 165-170	5.6	16
12	Diagnostic strategy with a solid pancreatic mass. <i>Presse Medicale</i> , 2019 , 48, e125-e145	2.2	11
11	The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. <i>Digestive and Liver Disease</i> , 2019 , 51, 735-740	3.3	10
10	Long-Term Pancreatic Functional Impairment after Surgery for Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
9	Local treatment for focal progression in metastatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019 , 26, 405-409	5.7	7
8	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. <i>Annals of Surgery</i> , 2019 , 270, 422-433	7.8	33

7	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2019 , 9, 18614	4.9	12
6	Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). <i>Pancreatology</i> , 2019 , 19, 57-63	3.8	5
5	Ct radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. <i>Physica Medica</i> , 2019 , 57, 41-46	2.7	14
4	A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. <i>Hpb</i> , 2018 , 20, 197-203	3.8	20
3	The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 778-783	3.6	38
2	How should incidental NEN of the pancreas and gastrointestinal tract be followed?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018 , 19, 139-144	10.5	4
1	Guideline for the Management of Pancreatic Neuroendocrine Tumor 2017 , 161-172		